Travere Therapeutics Inc. has announced the issuance of inducement equity grants to 17 new employees, as approved by the Compensation Committee of its Board of Directors on July 10, 2025. These grants consist of restricted stock units (RSUs) covering a total of 121,700 shares of the company's common stock. The RSUs, though issued outside of Travere's 2018 Equity Incentive Plan, adhere to its terms and were granted under Nasdaq Listing Rule 5635(c)(4) as part of the company's strategy to attract new talent. The RSUs will vest over a four-year period, with 25% of the shares vesting on each anniversary of the grant date, contingent upon the continued service of the employees with the company through the vesting dates.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。